Metropolitan Life Insurance Company (MetLife)’s Arcturus Therapeutics ARCT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,394	Closed	-$47.1K	–	165
2024 Q1	$47.1K	Hold	1,394	–	–	﹤0.01%	1436
2023 Q4	$44K	Hold	1,394	–	–	﹤0.01%	1515
2023 Q3	$35.6K	Hold	1,394	–	–	﹤0.01%	1582
2023 Q2	$40K	Hold	1,394	–	–	﹤0.01%	1563
2023 Q1	$33.4K	Hold	1,394	–	–	﹤0.01%	1613
2022 Q4	$23.6K	Hold	1,394	–	–	﹤0.01%	1922
2022 Q3	$20.7K	Hold	1,394	–	–	﹤0.01%	2015
2022 Q2	$21.9K	Hold	1,394	–	–	﹤0.01%	2010
2022 Q1	$37.6K	Sell	1,394 -4,915	-78%	-$125K	﹤0.01%	1749
2021 Q4	$233K	Hold	6,309	–	–	﹤0.01%	1922
2021 Q3	$301K	Buy	6,309 +62	+1%	+$2.78K	﹤0.01%	1764
2021 Q2	$211K	Hold	6,247	–	–	﹤0.01%	2103
2021 Q1	$258K	Hold	6,247	–	–	﹤0.01%	1838
2020 Q4	$271K	Buy	6,247 +1,517	+32%	+$103K	﹤0.01%	1737
2020 Q3	$203K	Buy	4,730 +556	+13%	+$27.6K	﹤0.01%	1763
2020 Q2	$195K	Buy	+4,174	New	+$144K	﹤0.01%	1811

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ARCT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 1,394 shares — an estimated $47.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ARCT in Q2 2020 and held it in 16 quarters. The position peaked at $301K in Q3 2021. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,394 Arcturus Therapeutics shares in Q2 2024, an estimated $47.1K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 16 quarters.
Metropolitan Life Insurance Company (MetLife)'s Arcturus Therapeutics position peaked at $301K in Q3 2021.
170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.